Established in 2012, Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea.
In 2015 the company launched Remsima, the world’s first biosimilar monoclonal antibody (mAb) to be approved by the European Medicines Agency (EMA).
In November 2018 Celltrion Healthcare, the marketing arm of the company, won a huge deal in France with big tenders for Herzuma, a biosimilar of Roche’s blockbuster breast cancer treatment Herceptin.
Celltrion continues to concentrate its capacities on the development of innovative novel biologics, such as bio-betters, ADC, and therapeutic agents for influenza, based on the technologies and production capacities accumulated through developing the antibody biosimilar.
In 2018, Celltrion was ranked #82 on Forbes Top Regarded Companies List and #14 on their World’s Most Innovative Companies List.
Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far…
Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global biopharmaceutical company. Its general manager for Turkey, SeokHoon…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
Korean biotech SK Bioscience, known for bringing forward the first South Korean-developed COVID-19 vaccine, is pursuing its beyond-COVID growth strategy with a new green light for its SKYCellflu vaccine. The…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
See our Cookie Privacy Policy Here
